|
|
|
Info: Your browser does not accept cookies. If you want to put products into your cart and purchase them you need to enable cookies.
Browse
Deployment of Antibody Technologies in Oncology
The discovery of new cancer therapeutics has seen a significant shift towards biologicals as an alternative to small molecule drugs. Targeted biologics utilizing monoclonal antibody-based technologies have rapidly developed into one of the major marke
RNA therapy: the next big thing after monoclonal antibodies?
Detailed review of RNA therapy, encompassing analysis of the development pipeline, technologies available and target markets. The report aims to help establish whether RNA therapy can provide the next wave of growth after monoclonal antibodies.
The Future of Targeted Therapeutics
This report examines various types of targeted therapies within Pharma pipelines, highlighting the molecules of greatest significance to major therapy areas.
Cancer Antibodies: Competitive Positioning for Success
This report is written for you to identify your competition and understand which targeting strategies are at work within antibody drug development. It allows you to pin-point which competitors drugs’ clinical out-come may have bearing on your ow
Monoclonal Antibodies Report: 2008 Update
Detailed analysis of the monoclonal antibody segment, encompassing market dynamics, key therapy areas, technology and target types through to 2013, evaluating the strategies companies are using to capitalize on this lucrative market.
Triple Analysis: Lymphoma, PK Inhibitors & Antibodies
In this triple analysis report BioSeeker Group has analyzed three major and intertwined areas of cancer R&D, Lymphoma, Protein Kinase Inhibitors and Therapeutic Antibodies, which are all subjects to an extensive number of innovative drug candidates. T
The Future of Monoclonal Antibodies Therapeutics
A key theme of this report is the high level of innovation, as demonstrated by advancements in antibody engineering with the introduction of chimeric, humanized and fully human mAbs. Other innovation in antibody technology include advancements in non
The Complete Guide to Targeted Therapies in Oncology
In this comprehensive report covering targeted therapies in oncology, BioSeeker Group has analyzed apoptopic agents, protein kinase inhibitors, anti-angiogenic and vascular targeting agents, immunostimulators, antibodies and vaccines in oncology.
Triple Analysis: NSCLC, PK Inhibitors & Anti-Angiogenic Agents
p>In this triple analysis report BioSeeker Group has analyzed three major and intertwined areas of cancer R&D, Non Small Cell Lung Cancer Therapeutics, Protein Kinase Inhibitors and Anti-angiogenesis and Vascular Targeting in Oncology, which are all s
Pipeline Insight: Therapeutic Cancer Vaccines
Unmet needs across the cancer market remain high, with most therapies conferring low levels of specificity and high toxicity. Therapeutic cancer vaccines offer an attractive therapeutic addition, delivering treatment of high specificity, low toxicity
Monoclonal Antibodies 2007
This report provides an analytically-based overview of the growing market for therapeutic monoclonal antibodies, which represent the largest segment of protein-based therapeutics.
Results 1 - 15 of 15
|
Latest News
|
Expert Views: Are the US and emerging markets ready for the generic drug boom? |
|
Read more...
|
|
Expert Views: Cytotoxic therapies to feel sting of generics |
|
Read more...
|
|
Expert Views: Hope for Obama's healthcare IT plan |
|
Read more...
|
|
|
